UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

10 Nov 2023

UCB Presents New Five-Year Data on BIMZELX[®]▼(bimekizumab) in Ankylosing Spondylitis at ACR Convergence 2023

Read More
9 Nov 2023

UCB successfully completes its offer to the public of fixed rate notes and decides to early terminate the subscription period

Read More
7 Nov 2023

UCB launches an offer to the public of 6-year 5.20% fixed rate notes in Belgium and in Luxembourg

Read More
1 Nov 2023

UCB presents latest data from generalized myasthenia gravis portfolio at 2023 AANEM Annual Meeting and MGFA Scientific Session

Read More
18 Oct 2023

BIMZELX[®] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

Read More
17 Oct 2023

UCB announces U.S. FDA approval of ZILBRYSQ[®] (zilucoplan) for the treatment of adults with generalized myasthenia gravis

Read More

Stay up-to-date on the latest news and information from UCB